Showing results (1-10 of 720) with videos related to
Sort By:
Pageof 72
Herz|February 1, 1986
Coronary thrombolysis with clot-selective plasminogen activatorsD Collen, H BounameauxBlood|May 1, 1986
Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbitsH Bounameaux, J M Stassen, C Seghers, et al.Circulation|March 1, 1986
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarctionD Collen, H Bounameaux, F De Cock, et al.Thrombosis Research|October 15, 1985
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusionH Bounameaux, P Gresele, M Hanss, et al.The Journal of Pharmacology and Experimental Therapeutics|November 1, 1985
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humansM Verstraete, H Bounameaux, F de Cock, et al.Revue De Pneumologie Clinique|October 14, 1998
[Does D-dimer determination allow the exclusion of pulmonary embolism?]H BounameauxJournal Des Maladies Vasculaires|January 1, 1994
[Hemorrhagic complications of anticoagulants in angiology]H BounameauxTherapeutische Umschau. Revue Therapeutique|April 1, 1996
[Drug therapy of deep venous thrombosis]H BounameauxAgressologie: Revue Internationale De Physio-Biologie Et De Pharmacologie Appliquees Aux Effets De L'Agression|March 1, 1990
[Epidemiology and etiopathogenesis of deep venous thrombosis of the lower limbs]H BounameauxJournal of Internal Medicine|July 15, 2010
Contemporary management of pulmonary embolism: the answers to ten questionsH BounameauxPageof 72